CONNEQT Health

Investor Update | Q4, 2026

Four Numbers From the Quarter

Recurring revenue and enterprise adoption both grew over the June quarter.

CONSUMER

$1.3M

Consumer revenue

+21% QoQ (or 34% on a constant currency basis)

DIGITAL

+71%

Digital growth (Care+ in-app purchases)

$68K recurring

ENTERPRISE

$94K

Cumulative clinical subscription ARR

+70% QoQ

ENTERPRISE

7

New clinical subscription agreements signed

$64.5K contract value

The transition from one-off equipment sales to subscription-anchored revenue

- Digital rose from 4% to 5% of consumer cash receipts (+100 bps)
- Cumulative enterprise contract value grew 65% to $163.8K

QUARTER HIGHLIGHTS

Consumer: Record Revenue *Achieved US$1M of Cash Receipts*

Continued momentum driven by Pulse adoption, digital expansion, and strategic partnerships.

12,000+ Pulse devices deployed



3,574
Pulse devices sold
+33% QoQ

A$68K
Digital purchases
+71%

4% → 5%
Digital share of consumer purchases
+100 bps QoQ

QUARTER HIGHLIGHTS

Enterprise: Building a Recurring Revenue Platform

Contracted ARR and TCV increased 70% and 65% QoQ, validating the subscription-first strategy.



7 new

Clinical subscription agreements this quarter

$38.8K new ARR added

$64.5K

Total contract value signed this quarter

incl. $25.7K implementation fees

Subscription-first

Recurring model replacing one-time sales

Predictable, expandable accounts

Group: Another Quarter of Strong Execution

Consumer momentum, research stability and enterprise progress drove another quarter of growth.



$2.1M

Q4 Group revenue

+7% QoQ

$10M

Annualised run-rate of Group revenue and other income

Driven by Pulse and research growth

Q4 FY26 Commercial Highlights

Total Clinical Subscription Base

11 advanced testing locations
Expanding arterial health assessments across a 70-location franchise network.

6 Concierge medical groups
Embedding arterial health into premium preventive and longevity-focused care.

CONNEQT Pulse Partnerships

CONNEQT Pulse to be featured in an AARP print mailer with a distribution of approximately 55 million.

CONNEQT Pulse selected for inclusion in Blueprint's Protocol Marketplace, with launch targeted for August.



Continued progress toward an H1 FY27 pilot for CONNEQT Pulse integration into a national primary care platform's next-generation health station.

QUARTERLY SCORECARD

Progress Against Last Quarter's Commitments

The priorities set out in the Q3 FY26 update, and where each now stands.

WHAT WE TOLD YOU LAST QUARTER	WHERE IT STANDS NOW	
Sustain strong double-digit quarterly Pulse sales growth	Consumer revenue +21% QoQ (34% on a constant currency basis) to $1.3M, and the first quarter to receive US$1.0M in cash receipts	MET
Deliver a best-in-class app to drive adoption & retention	Digital revenue +71% QoQ; NCOA Best Advanced BP Monitor 2026; App v2 in build	MET
Scale enterprise adoption & recurring in-clinic assessment ARR	Clinical subscription ARR +70% to $94.2K; 7 new agreements; TCV +65%	MET
Expand pharmaceutical and research partnerships	U.S. Phase 2b pharma trial progressing; research pipeline continuing to strengthen.	MET

QUARTERLY SCORECARD

Progress Against Last Quarter's Commitments

The priorities set out in the Q3 FY26 update, and where each now stands.

WHAT WE TOLD YOU LAST QUARTER	WHERE IT STANDS NOW	
Launch arterial health analytics services (SphygmoCloud / BaaS)	SphygmoCloud advancing; FDA Pre-Submission scheduled; Pulse SDK & BaaS progressing	IN PROGRESS
Establish a clear, capital-efficient path to profitability	Global distribution restructured to a leaner, Australia-led model	IN PROGRESS

Priorities for FY27

We’re Transitioning Across Three Axes Simultaneously

Hardware → Cloud Platform

Value-Add

Shifts value creation from hardware to software, analytics, and data infrastructure

Execution Risks

- SaMD regulatory requirements
- Cloud and cybersecurity modernization
- Legacy architecture transition complexity

Transactional → Recurring Revenue

Value-Add

Expands lifetime customer value and improves revenue durability

Execution Risks

- Commercial model evolution
- Pricing and packaging transition
- Sales enablement and channel alignment

Single Device → Ecosystem

Value-Add

Positions CQT as the platform for arterial health and cardiovascular biomarker services

Execution Risks

- Integration and interoperability requirements
- Resource prioritization across initiatives
- Balancing proprietary vs ecosystem strategy

Priorities for the Year Ahead

Directional priorities across the year

Platform & Technology

H1 FY27 · now underway	H2 FY27 · scaling	Exiting FY27 · platform
Advance SphygmoCloud & FDA pathway; roll out Pulse SDK	Build the Biomarker-as-a-Service foundation	Transition device-led → SaaS & data platform; SphygmoCor-powered integrations across devices

Forward priorities are directional and do not constitute guidance. No numeric forecasts provided (ASX continuous-disclosure).

FY27 ROADMAP

Priorities for the Year Ahead

Directional priorities across the year

Enterprise

H1 FY27 · now underway	H2 FY27 · scaling	Exiting FY27 · platform
Accelerate advanced-testing, concierge, longevity & performance segments	Reference-led growth across multi-location networks	Expand analytics to pharma & clinical-trial partners; scale distribution across clinics & insurers
Launch arterial health analytics services	Grow utilisation & cardiology-report revenue	

Forward priorities are directional and do not constitute guidance. No numeric forecasts provided (ASX continuous-disclosure).

Priorities for the Year Ahead

Directional priorities across the year

Consumer

H1 FY27 · now underway	H2 FY27 · scaling	Exiting FY27 · platform
Expand installed base; grow premium subscription adoption	Launch CONNEQT App v2 — Arterial Age, telehealth, premium features	Pulse V.2 (OTC) expansion
Enhance onboarding & lifecycle marketing		

Forward priorities are directional and do not constitute guidance. No numeric forecasts provided (ASX continuous-disclosure).

How It Comes Together

SphygmoCor® Cloud


CONNEQT Health
Cardiology Report (Oct 2024 - Jan 2025)
General Details
Cardiovascular Risk Profile - Arterial Intelligence™
Low Cardiovascular Risk
Intermediate Cardiovascular Risk
High Cardiovascular Risk

Analytics

Data Lake

Algorithm

CONNEQT Pulse

Legacy, doesn't speak cloud and we are exploring how to do so w/o triggering regulatory review.

SphygmoCor XCEL

Pulse + all future devices store data in the Data Lake

CONNEQT V2

XCEL V2

V2+ will do all biomarker extraction in the cloud. No local processing. They also become demonstrator device for 3rd party integration.

TODAY

TOMORROW

Biomarker-as-a-Service (BaaS)

On-demand vascular biomarker extraction for digital health applications

Health Intelligence Marketplace

AI-driven real-world vascular health data for population analytics

Our mobile apps interface between the hardware and cloud components to enable data capture, device orchestration, report delivery, and patient engagement across clinical and consumer environments.

MOBILE



TABLET

We are building the market from both directions

From the customer upward *— consumers and clinicians paying today for arterial health insight.* ***From the system downward*** *— the evidence, economics and policy for population scale.*

SYSTEM DOWNWARD ↓

CUSTOMER UPWARD ↑

1

Found a higher-value use

Interpretation, not hardware

2

Validated with wallets

~75% chose the one-year plan

3

Pulled into clinics

Clinicians came to us — not a sales push

4

Converted to recurring revenue

XCEL clinical subscription layer

5

Building national scale

Align with public health priorities

Heart attacks cost the US $85B/yr, what if we screened for its risk?



Distribution of heart attacks by age

Mammograms before breast cancer symptoms

Colonoscopies before colorectal cancer develops

Arterial health assessments before the first heart attack?

CONNEQT Health

BUILDING FROM BOTTOM UP AND TOP DOWN

We are not waiting for this market — we already building it

SYSTEM DOWN — THE CASE FOR SCREENING

US$85B problem

Heart-attack burden, 65% of it lost productivity

Prevention is accessible

A 1% reduction funds screening for every American 40–59 @ $850m/yr

Evidence & policy

Science, playbook and policy pathways built through PLS

CUSTOMER UP — ALREADY HAPPENING

Consumers pay

~75% of Care+ subscribers chose the one-year package

Clinicians pull

Practices came to us to offer the same assessment

Recurring revenue

XCEL clinical subscriptions — assessment, reporting, support

Arterial health as routine prevention

Near-term execution: subscriptions, clinic deployment, recurring revenue.
Long-term opportunity: routine prevention at population scale.

Corporate

Oversubscribed Placement, Now Fully Funded

Strong Support from Regal Funds Management, high net worth shareholders and the Board.

Oversubscribed by $2.0 Million Capital Raised

An additional $2.0 million funds raised, the placement was launched at approximately $3.5 million and upsized to $5.5 million on the back of strong investor demand.

Strong Take Up

The placement received strong support from Regal Funds Management (leading fund manager with ~$20bn AUM). Strong support was also received from existing shareholders and the board.

Highly Supportive Register

Strengthening of the register with long-term existing shareholders as the CONNEQT enters its next phase of growth. The placement enabled existing HNW shareholders the opportunity to increase their pro-rata holdings, while the SPP allows retail shareholders to participate.

Bookbuild Breakdown



Bookbuild Breakdown

(Tranche One)



Share Purchase Plan

Eligible shareholders can apply for up to A$30,000 in new CQT shares

A limited-time opportunity to participate in CONNEQT's next phase of growth — with the SPP currently expected to close on Friday, 24 July 2026.

KEY SPP TERMS

1. **Target raise**
   CONNEQT is targeting $0.5 million under the SPP.
2. **Company discretion**
   The Company may close early, scale back applications, or accept an amount above or below the target depending on demand.
3. **Pro-rata scale back**
   Any scale back will be conducted on a pro-rata basis as set out in the SPP terms.

Now	24 Jul	30 Jul	31 Jul	3 Aug
SPP open	SPP closes	Demand / Scale back	Allotment	Quotation

How to participate

Action required before close

1. **Read the booklet**
   Sent by email or post; also available via ASX announcements for CQT.
2. **Apply & pay**
   Follow the personalised application and payment instructions in the SPP booklet.
3. **Submit by close**
   5pm Sydney time, Friday 24 July 2026.

Questions?

+61 2 9874 8761 · consult your financial or professional adviser

Eligible shareholders should read the SPP booklet in full for eligibility, offer terms, application instructions and timetable details. Indicative timetable is subject to change without notice.

CONNEQT®
Health